<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05037591</url>
  </required_header>
  <id_info>
    <org_study_id>7171011P321452021061500018</org_study_id>
    <nct_id>NCT05037591</nct_id>
  </id_info>
  <brief_title>Effect of Sea Grapes-antioxidants Extract in Obese Men : 4 Weeks Randomized-Double Blind Controlled Trial</brief_title>
  <official_title>Effect of Sea Grapes-antioxidants Extract in Obese Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State Islamic University of Sunan Kalijaga Yogyakarta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>State Islamic University of Sunan Kalijaga Yogyakarta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Doses of 150 mg/kg BW (30 mg/200g BW) sea grape extract in a previous pre-clinical trial,&#xD;
      showed that it could improve blood glucose, total cholesterol and serum PGC-1 levels in rats&#xD;
      fed a diet high in fat and cholesterol. In addition, you also have hepatoprotective activity&#xD;
      (aka non-toxic) in diabetic mice. Previous research, is an in vivo (Pre-clinical) study that&#xD;
      has not represented the benefits or efficacy of sea grape extract on variables tested in&#xD;
      humans. Therefore, this clinical trial was conducted to support the effect of sea grape&#xD;
      extract-antioxidant on blood glucose, total cholesterol, and PGC-1 levels in obese men for 4&#xD;
      weeks using a Randomized-Double Blind Controlled Trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was a 4-week, randomized, double-blind, placebo-controlled clinical trial followed&#xD;
      by a 1-week screening period. Participants who respond to the invitation and meet the entry&#xD;
      criteria during the telephone screening interview are scheduled for the initial visit.&#xD;
      Evaluation during the initial visit includes physical examination in the form of BMI (Body&#xD;
      Mass Index) based on Asia-Pacific guidelines and blood parameter screening tests in the form&#xD;
      of blood glucose, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein&#xD;
      (LDL) and total cholesterol, and PGC-1α were performed on all participants within 1 week of&#xD;
      the initial screening. A random number between 1 and 70 was generated for each subject and&#xD;
      registered participants were scheduled for their first visit and randomly assigned to the sea&#xD;
      grape extract group (n=35) or placebo (n=35). Sea grape extract/placebo tablets/capsules were&#xD;
      given to participants every 1 week (1 day of consumption per oral) 15 Minutes before eating&#xD;
      (According to the diabetes drug guidline consumtion).&#xD;
&#xD;
      During the 4-week intervention period, participants were asked to continue their usual diet&#xD;
      and not to consume functional foods or other dietary supplements. Anthropometry (BMI), Waist&#xD;
      Hip Ratio (WHR) , blood parameters, urine profile (Marker of toxicity), and nutrient intake&#xD;
      of both groups were measured before and after the intervention period. During the trial&#xD;
      phase, all participants were instructed to maintain their normal diet and physical activity.&#xD;
      Each week participants were asked to report assessments of side effects or changes in&#xD;
      training, lifestyle, or diet; and to evaluate tablet compliance.&#xD;
&#xD;
      Subjects/Participants The study participants were recruited during 2021 at Manado, Republic&#xD;
      of Indonesia. A total of 150 participants agreed to participate in the study. Only&#xD;
      individuals men who are obese (BMI ≥ 25 kg m-2 and Waist Hip Ratio (WHR) ≥ 0.90) according to&#xD;
      Asia-Pacific guidelines and have not been diagnosed with other diseases were included in the&#xD;
      study. To meet guidelines for evaluating the efficacy of functional food referring to the&#xD;
      Korea Food and Drug Administration (because Indonesia does not yet exist and Koreas belong to&#xD;
      one Asian region so used), very obese participants (BMI ≥ 30 kg m-2) were not included in the&#xD;
      study.&#xD;
&#xD;
      In total, 70 participants met the research criteria (age 29.98 ± 3.26 year; weight, ..... ±&#xD;
      .... kg; BMI, .... ±.... kg m-2) and were randomly divided into two groups (n = 35 each)&#xD;
      given sea grape extract 1.68 g/70kg BB day-1) or placebo (1.68 g/70kg BB day-1). The&#xD;
      exclusion criteria for this study are as follows: (a) significant weight variation (over 10%)&#xD;
      in the last 3 months; (b) a history of cardiovascular disease including arrhythmia, heart&#xD;
      failure, or myocardial infarction, diabetes mellitus (DM) and the use of pacemakers; (c) a&#xD;
      history of conditions that may interfere with test products or inhibit their absorption such&#xD;
      as gastrointestinal diseases (Crohn's disease) or surgeries that have been experienced&#xD;
      (caesarean section or enterocele); (d) participation in other clinical trials in the last 2&#xD;
      months; (e) abnormal liver function; (f) a history of kidney disease (eg, acute or chronic&#xD;
      renal failure and nephrtic syndrome); (g) undergo antipsychotic drug therapy within the last&#xD;
      2 months; (h) laboratory test results as well as medical or psychological conditions that may&#xD;
      interfere with successful participation in research assessed by researchers; (i) a history of&#xD;
      alcohol or substance abuse; and (j) allergy or hypersensitivity to any of the ingredients in&#xD;
      the test product; (k) is neither a passive nor an active smoker. All participants give&#xD;
      written consent before the investigation begins. The research protocol was submitted to the&#xD;
      Health Research Ethics Commission (KEPK) of The General Hospital of Education Prof. Dr. RD.&#xD;
      Kandou (Manado, Republic of Indonesia) online at http://sim-epk.keppkn.kemkes.go.id. All&#xD;
      protocols referred to The Declaration of Helsinki and The Council for International&#xD;
      Organizations of Medical Sciences (CIOMS).&#xD;
&#xD;
      Measurement of Efficacy Results A total of 70 participants who met the research criteria were&#xD;
      asked to visit the clinic once every 1 week (0th, 1st, 2nd, 3rd, and 4th/last week of the&#xD;
      study period) with a total of 5 clinical visits including initial examination. During each&#xD;
      visit, the use of the supplement is currently reviewed and symptoms or side effects are&#xD;
      noted. During screening visits, demographic and lifestyle information is collected (age,&#xD;
      alcohol consumption, and smoking habits). Medical history is taken and urine turbidity tests&#xD;
      are carried out.&#xD;
&#xD;
      The following parameters are assessed; Weight, Height, WHR and BMI during each visit. Blood&#xD;
      samples were collected after a minimum of 12 hours of fasting during initial screening as&#xD;
      well as in the 0, 2nd and 4th weeks of the intervention period to obtain blood glucose&#xD;
      profiles, total cholesterol, triglycerides, high-density lipoprotein (HDL), low-density&#xD;
      lipoprotein (LDL) and PGC-1α. Blood samples were taken from the arm vein. The arm vein to be&#xD;
      punctured is cleaned with 70% alcohol and allowed to dry. A tourniquet is placed on the upper&#xD;
      arm to expose and slightly accentuate the veins. The skin is stretched over the vein with the&#xD;
      fingers of the left hand so that the vein cannot move. The skin is pierced with a needle and&#xD;
      syringe with the right hand until the tip of the needle enters the lumen of the vein. The&#xD;
      tourniquet is removed and slowly withdraw the syringe suction until the desired amount of&#xD;
      blood is obtained. A 70% alcohol swab is placed over the needle and the syringe and needle&#xD;
      are removed. The needle is removed from the syringe and the blood sample is transferred into&#xD;
      a vacutainer tube.&#xD;
&#xD;
      Evaluation of Safety and Diet&#xD;
&#xD;
      The safety of the extract is assessed by the following procedure. Urine Test Strips 10 Verify&#xD;
      Parameters, Parameters examined are:&#xD;
&#xD;
        -  Glucose (50 -100 mg / dl)&#xD;
&#xD;
        -  Protein (7.5 - 15 mg / dl)&#xD;
&#xD;
        -  pH (5-9)&#xD;
&#xD;
        -  Leukocytes (9-15 leu / ul)&#xD;
&#xD;
        -  Nitrite (0.05-0.1 mg/ dl)&#xD;
&#xD;
        -  Urobilinogen (0.2-1.0 mg / dl)&#xD;
&#xD;
        -  Blood (5-10 Ery/ul)&#xD;
&#xD;
        -  Ketones (2.5-5 mg/dl)&#xD;
&#xD;
        -  Bilirubin (0.4-1.0 mg/ dl)&#xD;
&#xD;
        -  Specific Gravity (SG) (1,000-1,030) Test the urine parameters above using Urinalysis 10U&#xD;
           Reagent Strips Verify (REF U031-102 exp. 2022-03-05). Pulse rate and blood pressure are&#xD;
           measured on each visit after a 5-minute break using intelliVue MP70 (Philips,&#xD;
           Netherlands). Personal reports are also recorded at these times. We kept the subjects&#xD;
           maintaining their usual diet and activity, and all participants completed diet records&#xD;
           on each visit to the clinic during the intervention period to evaluate their energy&#xD;
           intake and diet quality. Food intake data were analyzed by a nutritionist (Melvin Junior&#xD;
           Tanner, S.Gz).&#xD;
&#xD;
      Statistical Analysis Statistical analysis is performed using SPSS software, version 26 (IBM&#xD;
      Corporation). Fixed effects include treatment groups, treatment visits, and interactions&#xD;
      between treatment and visit groups. The value p&lt;0.05 is considered statistically significant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Actual">September 15, 2021</completion_date>
  <primary_completion_date type="Actual">September 7, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study was a 4-week, randomized, double-blind, placebo-controlled clinical trial. Evaluation during the initial visit includes physical examination in the form of Body Mass Index based on Asia-Pacific guidelines and blood parameter screening tests in the form of blood glucose, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL) and total cholesterol, and PGC-1α were performed on all participants within 1 week of the initial screening. A random number between 1 and 70 was generated for each subject and registered participants were scheduled for their first visit and randomly assigned to the sea grape extract group (n=35) or placebo (n=35). Sea grape extract/placebo tablets/capsules were given to participants every 1 week (1 day of consumption per oral) 15 Minutes before eating (According to the diabetes drug guidline consumtion).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peroxisome proliferator-activated receptor (PPAR)-γ coactivator 1 alpha (PGC-1α) Levels &quot;change&quot; is being assessed</measure>
    <time_frame>Change from Baseline PGC-1α Levels at 4th weeks of the intervention period</time_frame>
    <description>Evaluate PGC-1α level in pg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Cholesterol &quot;change&quot; is being assessed</measure>
    <time_frame>Change from Baseline Total Cholesterol at 4th weeks of the intervention period</time_frame>
    <description>Evaluate total Cholesterol level in mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Glucose &quot;change&quot; is being assessed</measure>
    <time_frame>Change from Baseline Blood Glucose at 4th weeks of the intervention period</time_frame>
    <description>Evaluate total blood sugar level in mg/dL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (BMI)</measure>
    <time_frame>Change from Baseline Body Mass Index (BMI) at 4th weeks of the intervention period</time_frame>
    <description>Body Mass Index (BMI) weight and height will be combined to report BMI in kg/m^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>Change from Baseline Triglycerides Levels at 4th weeks of the intervention period</time_frame>
    <description>Triglycerides in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>high-density lipoprotein (HDL)</measure>
    <time_frame>Change from Baseline high-density lipoprotein (HDL) Levels at 4th weeks of the intervention period</time_frame>
    <description>high-density lipoprotein (HDL) in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>low-density lipoprotein (LDL)</measure>
    <time_frame>Change from Baseline low-density lipoprotein (LDL) Levels at 4th weeks of the intervention period</time_frame>
    <description>low-density lipoprotein (LDL) in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight</measure>
    <time_frame>Change from Baseline Body Weight at 4th weeks of the intervention period</time_frame>
    <description>Weight in kilograms (kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Height</measure>
    <time_frame>Change from Baseline Body Height at 4th weeks of the intervention period</time_frame>
    <description>Height in meters (M)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>waist-to-hip ratio (WHR)</measure>
    <time_frame>Change from Baseline waist-to-hip ratio (WHR) at 4th weeks of the intervention period</time_frame>
    <description>This is calculated as waist measurement divided by hip measurement (W⁄H). For example, a person with a 30&quot; (76 cm) waist and 38&quot; (97 cm) hips has a waist-hip ratio of about 0.78.</description>
  </secondary_outcome>
  <number_of_arms>40</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Obesity</condition>
  <condition>Aging</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>placebo A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo E</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo F</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo G</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo H</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo I</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo J</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo K</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo L</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo M</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo N</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo O</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo Q</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo R</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo S</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo T</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo lactose powder (1.68 g/70kg BW day-1) or placebo tablets were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sea grape extract A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sea grape extract B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sea grape extract C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sea grape extract D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sea grape extract E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sea grape extract F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sea grape extract G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sea grape extract H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sea grape extract I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sea grape extract J</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sea grape extract K</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sea grape extract L</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sea grape extract M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sea grape extract N</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sea grape extract O</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sea grape extract P</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sea grape extract Q</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sea grape extract R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sea grape extract S</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sea grape extract T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>given sea grape extract 1.68 g/70kg BB day-1 were given to this group/arms</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sea grapes extract 1.68 g/70kg BW</intervention_name>
    <description>Contains antioxidants 45.66 ± 0.55% and Caulerpin. Sea grapes are usually consumed raw without any indication of poisoning.</description>
    <arm_group_label>sea grape extract A</arm_group_label>
    <arm_group_label>sea grape extract B</arm_group_label>
    <arm_group_label>sea grape extract C</arm_group_label>
    <arm_group_label>sea grape extract D</arm_group_label>
    <arm_group_label>sea grape extract E</arm_group_label>
    <arm_group_label>sea grape extract F</arm_group_label>
    <arm_group_label>sea grape extract G</arm_group_label>
    <arm_group_label>sea grape extract H</arm_group_label>
    <arm_group_label>sea grape extract I</arm_group_label>
    <arm_group_label>sea grape extract J</arm_group_label>
    <arm_group_label>sea grape extract K</arm_group_label>
    <arm_group_label>sea grape extract L</arm_group_label>
    <arm_group_label>sea grape extract M</arm_group_label>
    <arm_group_label>sea grape extract N</arm_group_label>
    <arm_group_label>sea grape extract O</arm_group_label>
    <arm_group_label>sea grape extract P</arm_group_label>
    <arm_group_label>sea grape extract Q</arm_group_label>
    <arm_group_label>sea grape extract R</arm_group_label>
    <arm_group_label>sea grape extract S</arm_group_label>
    <arm_group_label>sea grape extract T</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo lactose powder (1.68 g/70kg BW day-1).</description>
    <arm_group_label>placebo A</arm_group_label>
    <arm_group_label>placebo B</arm_group_label>
    <arm_group_label>placebo C</arm_group_label>
    <arm_group_label>placebo D</arm_group_label>
    <arm_group_label>placebo E</arm_group_label>
    <arm_group_label>placebo F</arm_group_label>
    <arm_group_label>placebo G</arm_group_label>
    <arm_group_label>placebo H</arm_group_label>
    <arm_group_label>placebo I</arm_group_label>
    <arm_group_label>placebo J</arm_group_label>
    <arm_group_label>placebo K</arm_group_label>
    <arm_group_label>placebo L</arm_group_label>
    <arm_group_label>placebo M</arm_group_label>
    <arm_group_label>placebo N</arm_group_label>
    <arm_group_label>placebo O</arm_group_label>
    <arm_group_label>placebo P</arm_group_label>
    <arm_group_label>placebo Q</arm_group_label>
    <arm_group_label>placebo R</arm_group_label>
    <arm_group_label>placebo S</arm_group_label>
    <arm_group_label>placebo T</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Only individuals men who are obese (BMI ≥ 25 kg m-2) according to Asia-Pacific&#xD;
             guidelines&#xD;
&#xD;
          -  Waist Hip Ratio (WHR) ≥ 0.90 according to Asia-Pacific guidelines and&#xD;
&#xD;
          -  not been diagnosed with other diseases were included in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  (a) significant weight variation (over 10%) in the last 3 months;&#xD;
&#xD;
          -  (b) a history of cardiovascular disease including arrhythmia, heart failure, or&#xD;
             myocardial infarction, diabetes mellitus (DM) and the use of pacemakers;&#xD;
&#xD;
          -  (c) a history of conditions that may interfere with test products or inhibit their&#xD;
             absorption such as gastrointestinal diseases (Crohn's disease) or surgeries that have&#xD;
             been experienced (caesarean section or enterocele);&#xD;
&#xD;
          -  (d) participation in other clinical trials in the last 2 months;&#xD;
&#xD;
          -  (e) abnormal liver function;&#xD;
&#xD;
          -  (f) a history of kidney disease (eg, acute or chronic renal failure and nephrtic&#xD;
             syndrome);&#xD;
&#xD;
          -  (g) undergo antipsychotic drug therapy within the last 2 months;&#xD;
&#xD;
          -  (h) laboratory test results as well as medical or psychological conditions that may&#xD;
             interfere with successful participation in research assessed by researchers;&#xD;
&#xD;
          -  (i) a history of alcohol or substance abuse; and&#xD;
&#xD;
          -  (j) allergy or hypersensitivity to any of the ingredients in the test product;&#xD;
&#xD;
          -  (k) is neither a passive nor an active smoker.&#xD;
&#xD;
          -  All participants give written consent before the investigation begins.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fahrul Nurkolis</last_name>
    <role>Principal Investigator</role>
    <affiliation>UIN Sunan Kalijaga Yogyakarta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fahrul Nurkolis</name>
      <address>
        <city>Manado</city>
        <state>Sulawesi Utara</state>
        <zip>95115</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <link>
    <url>https://www.elsevier.com/books/evaluation-of-drug-activities/laurence/978-1-4832-2845-7</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://doi.org/10.12688/f1000research.54952.1</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>State Islamic University of Sunan Kalijaga Yogyakarta</investigator_affiliation>
    <investigator_full_name>Fahrul Nurkolis</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Aging</keyword>
  <keyword>Functional Food</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Dyslipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Only measurement data with anonymized names will be shared.</ipd_description>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After research</ipd_time_frame>
    <ipd_access_criteria>repository</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 23, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT05037591/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

